Crosstalk between gut microbiota and COVID-19 impacts pancreatic cancer progression  

作　　者：Chun-Ye Zhang Shuai Liu Ming Yang 

机构地区：[1]Department of Veterinary Pathobiology,University of Missouri,Columbia,MO 65211,United States [2]The First Affiliated Hospital,Zhejiang University,Hangzhou 310006,Zhejiang Province,China [3]Department of Surgery,University of Missouri,Columbia,MO 65211,United States

出　　处：《World Journal of Gastrointestinal Oncology》2022年第8期1456-1468,共13页世界胃肠肿瘤学杂志（英文版）（电子版）

摘　　要：Pancreatic cancer(PC)is one of the most common causes of cancer-associated death worldwide,with a low rate of 5-year survival.Currently,the pathogenesis of PC is complicated,with no efficient therapy.Coronavirus disease 2019(COVID-19)disease caused by severe acute respiratory syndrome coronavirus 2 further exacerbates the challenge of patients with PC.The alteration of gut microbiota caused by COVID-19 infection may impact PC progression in patients via immune regulation.The expression of inflammatory immune mediators such as interleukin(IL)-6,IL-8,and IL-10 has been found to increase in both PC and COVID-19 patients,which is associated with the disease severity and prognostic outcome.Gut microbiome serves as a critical connector between viral infection and PC.It can regulate host systemic immune response and impact the efficacy of immunotherapy.Here,we first demonstrated the features of inflammatory cytokines in both diseases and their impact on disease outcomes.Then,we demonstrated the importance of immunotherapeutic strategies.This includes the immune modulation that targets a single or dual receptors using a single agent or their combinations for the treatment of PC in patients who get infected with COVID-19.Additionally,we explored the possibility of managing the disease by regulating gut microbiome.Overall,modulation of the lung-gut-pancreases axis can boost anti-cancer immunotherapy and reduce adverse prognostic outcomes.

关 键 词：COVID-19 SARS-CoV-2 Gut microbiota Pancreatic cancer INTERLEUKIN-6 INTERLEUKIN-8 INTERLEUKIN-10 Monoclonal antibodies Modulatory treatment 

分 类 号：R735.9[医药卫生—肿瘤]